Esperion Therapeutics, Inc. (ESPR)
USD 1.09
(10.77%)
USD 1.09
(10.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -150.1 Million USD | 12.13% |
| 2022 | -176.34 Million USD | 20.61% |
| 2021 | -222.14 Million USD | -84.28% |
| 2020 | -120.33 Million USD | -35.75% |
| 2019 | -88.72 Million USD | 56.48% |
| 2018 | -204.32 Million USD | -22.66% |
| 2017 | -166.53 Million USD | -123.57% |
| 2016 | -74.35 Million USD | -51.43% |
| 2015 | -49.02 Million USD | -36.45% |
| 2014 | -36.06 Million USD | -60.51% |
| 2013 | -22.68 Million USD | -121.66% |
| 2012 | -10.11 Million USD | -0.86% |
| 2011 | -10.06 Million USD | 0.0% |
| 2002 | -27.21 Million USD | -1.53% |
| 2001 | -26.8 Million USD | -23.39% |
| 2000 | -25.52 Million USD | -85.9% |
| 1999 | -11.68 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.58 Million USD | -164.22% |
| 2024 Q1 | 72.26 Million USD | 281.79% |
| 2023 FY | - USD | 12.13% |
| 2023 Q1 | -47.33 Million USD | -15.0% |
| 2023 Q4 | -42.36 Million USD | -53.86% |
| 2023 Q2 | -37.05 Million USD | 21.71% |
| 2023 Q3 | -27.53 Million USD | 25.7% |
| 2022 FY | - USD | 20.61% |
| 2022 Q4 | -41.15 Million USD | -0.73% |
| 2022 Q3 | -40.85 Million USD | 21.51% |
| 2022 Q2 | -52.05 Million USD | -22.44% |
| 2022 Q1 | -42.51 Million USD | 17.75% |
| 2021 Q4 | -51.68 Million USD | 7.0% |
| 2021 Q3 | -55.57 Million USD | -71.69% |
| 2021 Q2 | -32.37 Million USD | 60.84% |
| 2021 Q1 | -82.65 Million USD | 13.49% |
| 2021 FY | - USD | -84.28% |
| 2020 Q1 | -73.97 Million USD | -27.93% |
| 2020 FY | - USD | -35.75% |
| 2020 Q3 | -80.34 Million USD | -162.11% |
| 2020 Q4 | -95.54 Million USD | -18.92% |
| 2020 Q2 | 129.36 Million USD | 274.89% |
| 2019 Q4 | -57.82 Million USD | 10.06% |
| 2019 Q1 | 87 Million USD | 243.45% |
| 2019 Q2 | -55.24 Million USD | -163.5% |
| 2019 Q3 | -64.28 Million USD | -16.37% |
| 2019 FY | - USD | 56.48% |
| 2018 Q2 | -46.41 Million USD | 0.89% |
| 2018 FY | - USD | -22.66% |
| 2018 Q1 | -46.83 Million USD | -23.7% |
| 2018 Q4 | -60.64 Million USD | -20.11% |
| 2018 Q3 | -50.49 Million USD | -8.79% |
| 2017 Q1 | -40.4 Million USD | -39.92% |
| 2017 FY | - USD | -123.57% |
| 2017 Q4 | -37.85 Million USD | 16.08% |
| 2017 Q3 | -45.11 Million USD | -4.39% |
| 2017 Q2 | -43.21 Million USD | -6.96% |
| 2016 Q2 | -13.87 Million USD | 3.73% |
| 2016 FY | - USD | -51.43% |
| 2016 Q4 | -28.87 Million USD | -67.41% |
| 2016 Q3 | -17.25 Million USD | -24.34% |
| 2016 Q1 | -14.41 Million USD | -10.85% |
| 2015 Q3 | -12.61 Million USD | -3.38% |
| 2015 FY | - USD | -36.45% |
| 2015 Q2 | -12.2 Million USD | -8.26% |
| 2015 Q4 | -13 Million USD | -3.04% |
| 2015 Q1 | -11.27 Million USD | -20.92% |
| 2014 Q4 | -9.32 Million USD | 3.09% |
| 2014 Q1 | -7.86 Million USD | 18.77% |
| 2014 Q3 | -9.62 Million USD | -4.61% |
| 2014 FY | - USD | -60.51% |
| 2014 Q2 | -9.19 Million USD | -16.97% |
| 2013 FY | - USD | -121.66% |
| 2013 Q1 | -3.33 Million USD | -50.74% |
| 2013 Q2 | -4.25 Million USD | -27.4% |
| 2013 Q3 | -5.22 Million USD | -22.98% |
| 2013 Q4 | -9.67 Million USD | -85.13% |
| 2012 Q2 | -2.82 Million USD | -31.43% |
| 2012 Q4 | -2.21 Million USD | 25.09% |
| 2012 Q3 | -2.95 Million USD | -4.49% |
| 2012 Q1 | -2.15 Million USD | 0.0% |
| 2012 FY | - USD | -0.86% |
| 2011 FY | - USD | 0.0% |
| 2003 Q3 | -6.22 Million USD | 19.2% |
| 2003 Q2 | -7.83 Million USD | -7.44% |
| 2003 Q1 | -7.08 Million USD | -18.17% |
| 2002 Q2 | -7.3 Million USD | 7.46% |
| 2002 FY | - USD | -1.53% |
| 2002 Q3 | -7.23 Million USD | -6.71% |
| 2002 Q4 | -6.19 Million USD | 18.93% |
| 2002 Q1 | -7.35 Million USD | -15.95% |
| 2001 Q2 | -7.66 Million USD | 4.43% |
| 2001 FY | - USD | -23.39% |
| 2001 Q4 | -6.26 Million USD | -4.1% |
| 2001 Q3 | -6.29 Million USD | 20.78% |
| 2001 Q1 | -8.02 Million USD | -101.25% |
| 2000 Q2 | -7.56 Million USD | -34.33% |
| 2000 Q1 | -5.62 Million USD | 0.0% |
| 2000 Q3 | -7.75 Million USD | 42.76% |
| 2000 Q4 | -5.04 Million USD | 7.9% |
| 2000 FY | - USD | -85.9% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | -1355.551% |
| Safety Shot Inc | -12.18 Million USD | -1131.889% |
| Cosmos Health Inc. | -17.06 Million USD | -779.79% |
| Cronos Group Inc. | -72.14 Million USD | -108.053% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 83.77% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -316.019% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 516.608% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -4568.889% |
| ProPhase Labs, Inc. | -14.82 Million USD | -912.396% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -3217.304% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1652.948% |
| Radius Health, Inc. | 38.31 Million USD | 491.825% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -6284.83% |
| Alvotech | -484.86 Million USD | 69.041% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -3824.989% |
| Alpha Teknova, Inc. | -25.53 Million USD | -487.76% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 5.505% |
| SCYNEXIS, Inc. | 73.47 Million USD | 304.287% |
| Harrow Health, Inc. | 9.72 Million USD | 1643.844% |
| Biofrontera Inc. | -18.45 Million USD | -713.461% |
| DURECT Corporation | -24.68 Million USD | -508.119% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 252.763% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 237.311% |
| OptiNose, Inc. | -15.55 Million USD | -865.139% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 671.489% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 12799.492% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -21016.691% |
| SIGA Technologies, Inc. | 84.15 Million USD | 278.361% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 18586.207% |
| Shineco, Inc. | -26.55 Million USD | -465.295% |
| Phibro Animal Health Corporation | 84.6 Million USD | 277.418% |
| Procaps Group S.A. | 104.02 Million USD | 244.297% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -1686.787% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -4049.349% |
| Viatris Inc. | 3.51 Billion USD | 104.269% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -3824.989% |
| Rockwell Medical, Inc. | -4.69 Million USD | -3097.87% |
| Incannex Healthcare Limited | -18.5 Million USD | -711.219% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -14732.806% |
| Tilray Brands, Inc. | -72.84 Million USD | -106.071% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 148.685% |
| PetIQ, Inc. | 81.48 Million USD | 284.213% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2145.037% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 136.075% |
| Journey Medical Corporation | 1.92 Million USD | 7914.055% |
| Alimera Sciences, Inc. | 7.27 Million USD | 2163.057% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -3463.927% |
| Assertio Holdings, Inc. | -222.44 Million USD | 32.52% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -3661.493% |
| Embecta Corp. | 245.4 Million USD | 161.169% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -649.387% |
| Procaps Group, S.A. | 104.02 Million USD | 244.297% |
| PainReform Ltd. | -9.56 Million USD | -1468.691% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | -0.659% |
| Hempacco Co., Inc. | -12.77 Million USD | -1075.173% |
| Talphera, Inc. | -9.84 Million USD | -1425.178% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 192.149% |
| Alvotech | -484.86 Million USD | 69.041% |
| Lantheus Holdings, Inc. | 491 Million USD | 130.572% |
| Kamada Ltd. | 21.53 Million USD | 797.074% |
| Indivior PLC | 66 Million USD | 327.436% |
| Currenc Group, Inc. | -1.9 Million USD | -7798.035% |
| Evoke Pharma, Inc. | -7.29 Million USD | -1958.447% |
| Flora Growth Corp. | -45.87 Million USD | -227.247% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -649.387% |
| Evolus, Inc. | -41.81 Million USD | -259.024% |
| HUTCHMED (China) Limited | 25.52 Million USD | 688.013% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 162.166% |
| Akanda Corp. | -27.73 Million USD | -441.209% |